menu
    • menu
    [{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Beyond Air","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Private Placement","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Inhalation","sponsorNew":"Beyond Cancer \/ Beyond Air, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Beyond Air, Inc."},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"sGC","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Beyond Cancer \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Not Applicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Beyond Cancer \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Not Applicable"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Stanford School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Nitric Oxide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Beyond Cancer \/ Stanford School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Beyond Cancer \/ Stanford School of Medicine"},{"orgOrder":0,"company":"Beyond Cancer","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nitric Oxide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Beyond Cancer","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beyond Cancer \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Beyond Cancer \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Beyond Cancer

    Menu

    Beyond Cancer

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Beyond Cancer„¢ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable...

                            Details : UNO (nitric oxide) is a potent molecule, naturally synthesized in the human body. It is being evaluated in phase 1 clinical trials for advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors.

                            Brand Name : UNO

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 27, 2023

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Stanford School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, M...

                            Details : Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Stanford School of Medicine

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Meth...

                            Details : Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 13, 2022

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Beyond Cancer Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Show...

                            Details : Data suggests ultra-high concentration gaseous Nitric oxide (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune response.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 11, 2022

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Beyond Cancer

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Beyond Air

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Beyond Air® Announces $30 Million of Committed Capital in Previously Reported Beyond Cancer™ Private Placem...

                            Details : Beyond Cancer, including those owned by Beyond Air, will use the proceeds from the private placement for the safety and efficacy of the ultra-high concentration nitric oxide product, as well as its therapeutic potential in a number of indications.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 18, 2021

                            Lead Product(s) : Nitric Oxide

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Beyond Air

                            Deal Size : $30.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth